Genetic assessment of familial and early-onset Parkinson's disease in a Greek population

European Journal of Neurology

Volumn 21, Issue 7, 2014, Pages 963-968

  Bozi, M ^a,b   Papadimitriou, D ^c   Antonellou, R ^a   Moraitou, M ^d   Maniati, M ^e   Vassilatis, D K ^e   Papageorgiou, S G ^a   Leonardos, A ^a   Tagaris, G ^f   Malamis, G ^e   Theofilopoulos, D ^g   Kamakari, S ^g   Stamboulis, E ^a   Hadjigeorgiou, G M ^h   Athanassiadou, A ⁱ   Michelakakis, H ^d   Papadimitriou, A ^c,h   Gasser, T ^j   Stefanis, L ^a,e  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b HYGEIA HOSPITAL   (Greece)

^c HENRY DUNANT HOSPITAL   (Greece)

^d Institute of Child Health   (Greece)

^e BIOMEDICAL RESEARCH FOUNDATION   (Greece)

^f KAT HOSPITAL   (Greece)

^g Biogenomica Center for Genetic Research and Analyses SA   (Greece)

^h UNIVERSITY OF THESSALY   (Greece)

ⁱ UNIVERSITY OF PATRAS   (Greece)

^j UNIVERSITY OF TÜBINGEN   (Germany)

more..

Author keywords

Early onset; Familial; Genetics; Greece; Parkinson's disease

Indexed keywords

DJ 1 PROTEIN; GLUCOSYLCERAMIDASE; LEUCINE RICH REPEAT KINASE 2; PARKIN; PINK 1 PROTEIN; PROTEIN; SNCA PROTEIN; UNCLASSIFIED DRUG; ALPHA SYNUCLEIN; SNCA PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; AUTOSOMAL DOMINANT INHERITANCE; CONTROLLED STUDY; EARLY ONSET PARKINSON DISEASE; FAMILIAL DISEASE; FAMILIAL PARKINSON DISEASE; FEMALE; GENETIC ANALYSIS; GENETIC VARIABILITY; GREECE; HETEROZYGOTE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLEX LIGATION DEPENDENT PROBE AMPLIFICATION; NUCLEOTIDE SEQUENCE; ONSET AGE; PARKINSON DISEASE; POINT MUTATION; PRIORITY JOURNAL; VERY ELDERLY; GENETICS; MIDDLE AGED; PEDIGREE;

ADULT; AGE OF ONSET; AGED; AGED, 80 AND OVER; ALPHA-SYNUCLEIN; FEMALE; GREECE; HUMANS; MALE; MIDDLE AGED; PARKINSON DISEASE; PEDIGREE;

EID: 84902257960     PISSN: 13515101     EISSN: 14681331     Source Type: Journal    
DOI: 10.1111/ene.12315     Document Type: Article

References (29)

1. Neumann J, Bras J, Deas E, et al. Glucocerebrosidase mutations in clinical and pathologically proven Parkinson's disease. Brain 2009; 132: 1783-1794.
2. Benamer HT, de Silva R. LRRK2 G2019S in the North African population: a review. Eur Neurol 2010; 63: 321-325.
3. Vinish M, Prabhakar S, Khullar M, Verma I, Anand A. Genetic screening reveals high frequency of PARK2 mutations and reduced Parkin expression conferring risk for parkinsonism in North West India. J Neurol Neurosurg Psychiatry 2010; 81: 166-170.
4. Wang WW, Khajavi M, Patel BJ, Beach J, Jankovic J, Ashizawa T. The G209A mutation in the alpha-synuclein gene is not detected in familial cases of Parkinson disease in non-Greek and/or Italian populations. Arch Neurol 1998; 55: 1521-1523.
5. Correia Guedes L, Ferreira JJ, Rosa MM, Coelho M, Bonifati V, Sampaio C. Worldwide frequency of G2019S LRRK2 mutation in Parkinson's disease: a systematic review. Parkinsonism Relat Disord 2010; 16: 237-642.
6. Moraitou M, Hadjigeorgiou G, Monopolis I, et al. β-Glucocerebrosidase gene mutations in two cohorts of Greek patients with sporadic Parkinson's disease. Mol Genet Metab 2011; 104: 149-152.
7. Polymeropoulos MH, Lavedan C, Leroy E, et al. Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science 1997; 276: 2045-2047.
8. Nagarkatti R, Rao CB, Rishi JP, et al. Association of IFNG gene polymorphism with asthma in the Indian population. J Allergy Clin Immunol 2002; 110: 410-412.
9. Proukakis C, Dudzik CG, Brier T, et al. A novel α-synuclein missense mutation in Parkinson disease. Neurology 2013; 80: 1062-1064.
10. Kiely AP, Asi YT, Kara E, et al. α-Synucleinopathy associated with G51D SNCA mutation: a link between Parkinson's disease and multiple system atrophy? Acta Neuropathol 2013; 125: 753-769.
11. Papadimitriou A, Veletza V, Hadjigeorgiou GM, Patrikiou A, Hirano M, Anastasopoulos I. Mutated alpha-synuclein gene in two Greek kindreds with familial PD: incomplete penetrance? Neurology 1999; 52: 651-654.
12. Athanassiadou A, Voutsinas G, Psiouri L, et al. Genetic analysis of families with Parkinson disease that carry the Ala53Thr mutation in the gene encoding alpha-synuclein. Am J Hum Genet 1999; 65: 555-558.
13. Berg D, Niwar M, Maass S, et al. Alpha-synuclein and Parkinson's disease: implications from the screening of more than 1900 patients. Mov Disord 2005; 20: 1191-1194.
14. Kalinderi K, Bostantjopoulou S, Paisan-Ruiz C, Katsarou Z, Hardy J, Fidani L. Complete screening for glucocerebrosidase mutations in Parkinson disease patients from Greece. Neurosci Lett 2009; 452: 87-89.
15. Jasinska-Myga B, Kachergus J, Vilariño-Güell C, et al. Comprehensive sequencing of the LRRK2 gene in patients with familial Parkinson's disease from North Africa. Mov Disord 2010; 25: 2052-2058.
16. Orr-Urtreger A, Shifrin C, Rozovski U, et al. The LRRK2 G2019S mutation in Ashkenazi Jews with Parkinson disease: is there a gender effect? Neurology 2007; 69: 1595-1602.
17. Papapetropoulos S, Adi N, Shehadeh L, et al. Is the G2019S LRRK2 mutation common in all southern European populations? J Clin Neurosci 2008; 15: 1027-1030.
18. Kalinderi K, Fidani L, Bostantjopoulou S, Katsarou Z, Kotsis A. The G2019S LRRK2 mutation is uncommon amongst Greek patients with sporadic Parkinson's disease. Eur J Neurol 2007; 14: 1088-1090.
19. Xiromerisiou G, Hadjigeorgiou GM, Gourbali V, et al. Screening for SNCA and LRRK2 mutations in Greek sporadic and autosomal dominant Parkinson's disease: identification of two novel LRRK2 variants. Eur J Neurol 2007; 14: 7-11.
20. Spanaki C, Latsoudis H, Plaitakis A. LRRK2 mutations on Crete: R1441H associated with PD evolving to PSP. Neurology 2006; 67: 1518-1519.
21. Ross OA, Soto-Ortolaza AI, Heckman MG, et al. Genetic Epidemiology of Parkinson's Disease (GEO-PD) Consortium. Association of LRRK2 exonic variants with susceptibility to Parkinson's disease: a case-control study. Lancet Neurol 2011; 10: 898-908.
22. Leroy E, Anastasopoulos D, Konitsiotis S, Lavedan C, Polymeropoulos MH. Deletions in the Parkin gene and genetic heterogeneity in a Greek family with early onset Parkinson's disease. Hum Genet 1998; 103: 424-427.
23. Cruts M, Theuns J, Van Broeckhoven C. Locus-specific mutation databases for neurodegenerative brain diseases. Hum Mutat 2012; 33: 1340-1344.
24. Camacho JL, Jaramillo NM, Gómez PY, et al. High frequency of Parkin exon rearrangements in Mexican-mestizo patients with early-onset Parkinson's disease. Mov Disord 2012; 27: 1047-1051.
25. Sun M, Latourelle JC, Wooten GF, et al. Influence of heterozygosity for Parkin mutation on onset age in familial Parkinson disease: the GenePD study. Arch Neurol 2006; 63: 826-832.
26. Wang C, Ma H, Feng X, Xie S, Chan P. Parkin dosage mutations in patients with early-onset sporadic and familial Parkinson's disease in Chinese: an independent pathogenic role. Brain Res 2010; 1358: 30-38.
27. Pankratz N, Kissell DK, Pauciulo MW, et al. Parkin dosage mutations have greater pathogenicity in familial PD than simple sequence mutations. Neurology 2009; 73: 279-286.
28. Periquet M, Latouche M, Lohmann E, et al. Parkin mutations are frequent in patients with isolated early-onset parkinsonism. Brain 2003; 126: 1271-1278.
29. Lohmann E, Periquet M, Bonifati V, et al. How much phenotypic variation can be attributed to Parkin genotype? Ann Neurol 2003; 54: 176-185.